Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, Mikata A, Mukaida N, Matsushima K
Biomedical Research Institute, Kureha Chemical Industry, Tokyo, Japan.
Br J Cancer. 1995 Sep;72(3):708-14. doi: 10.1038/bjc.1995.398.
To study the effect of localised secretion of chemokines on tumour growth, the genes for human (hu) interleukin 8 (IL-8), hu-MCP-1 (MCAF), hu-MIP-1 alpha (LD78), murine (mu)-MCP-1 (JE), mu-MIP-1 alpha or mu-MIP-2 were introduced, via mammalian expression vectors, into Chinese hamster ovary (CHO) cells, and the ability of transfected cells to form tumours in vivo was evaluated. The production of hu-IL-8, hu-MIP-1 alpha or mu-MIP-1 alpha by transfected clones did not influence the growth rate in vitro, but drastically suppressed tumour growth when injected subcutaneously (s.c.) into nude mice. However, clones transfected with hu-MCP-1, mu-MCP-1 or mu-MIP-2 did not show any significant difference in growth rate in vivo compared with clones transfected with vector alone. Histological examination of the site of injection of CHO clones transfected with hu-IL-8, hu-MIP-1 alpha or mu-MIP-1 alpha showed predominantly neutrophilic infiltration. These results indicate that chemokines have potent anti-tumour activity when released, even at low doses, at the tumour site, which may be mediated by recruitment and targeting of neutrophilic granulocytes to chemokine-releasing cells. Our studies highlight the potential usefulness of localised chemokine secretion in inducing potent host anti-tumour defensive responses.
为研究趋化因子局部分泌对肿瘤生长的影响,通过哺乳动物表达载体将人(hu)白细胞介素8(IL - 8)、hu - MCP - 1(MCAF)、hu - MIP - 1α(LD78)、鼠(mu) - MCP - 1(JE)、mu - MIP - 1α或mu - MIP - 2的基因导入中国仓鼠卵巢(CHO)细胞,并评估转染细胞在体内形成肿瘤的能力。转染克隆产生的hu - IL - 8、hu - MIP - 1α或mu - MIP - 1α对体外生长速率没有影响,但皮下(s.c.)注射到裸鼠体内时会显著抑制肿瘤生长。然而,与仅用载体转染的克隆相比,用hu - MCP - 1、mu - MCP - 1或mu - MIP - 2转染的克隆在体内生长速率上没有显示出任何显著差异。对用hu - IL - 8、hu - MIP - 1α或mu - MIP - 1α转染的CHO克隆注射部位进行组织学检查显示主要为嗜中性粒细胞浸润。这些结果表明,趋化因子在肿瘤部位释放时,即使是低剂量,也具有强大的抗肿瘤活性,这可能是通过嗜中性粒细胞募集并靶向趋化因子释放细胞来介导的。我们的研究突出了局部趋化因子分泌在诱导有效的宿主抗肿瘤防御反应方面的潜在用途。